» Articles » PMID: 18292519

Expression of ICOS on Human Melanoma-infiltrating CD4+CD25highFoxp3+ T Regulatory Cells: Implications and Impact on Tumor-mediated Immune Suppression

Overview
Journal J Immunol
Date 2008 Feb 23
PMID 18292519
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Interaction of ICOS with its ligand (ICOSL, B7-H2) promotes T cell responses. As CD4+CD25highFoxp3+ naturally occurring T regulatory cells in melanoma patients express ICOS, we investigated the impact of ICOS on naturally occurring T regulatory cell function.

Methods: Expression of ICOS and T regulatory (Treg) cell markers was determined on CD4+CD25high T cells in PBMC and tumor-infiltrating lymphocytes from melanoma patients (n=10) and PBMC of normal controls (n=10) by multicolor flow cytometry. Suppression mediated by sorted ICOShigh and ICOSlow Treg was assessed in CFSE-based suppression assays with autologous CD4+CD25- responder cells (RC). Transwell inserts separating Treg from RC were used to evaluate suppression mechanisms used by Treg. ICOShigh or ICOSlow Treg were coincubated with RC+/-TCR and IL-2 stimulation. ICOShigh and ICOS- Treg were also expanded under conditions previously shown to induce Tr1 from RC.

Results: Treg in tumor-infiltrating lymphocytes expressed ICOS (mean fluorescence intensity=70+/-10), while Treg in PBMC had low ICOS expression (mean fluorescence intensity=3.5+/-2.5, p<or=0.001). ICOShigh Treg up-regulated Treg markers (p<or=0.0016) and mediated stronger suppression (p<or=0.001) relative to ICOSlow Treg. ICOShigh Treg induced Tr1 cells in nonactivated RC and Th2 cells in preactivated RC. ICOShigh Treg exposed to Tr1 cytokines expressed IL-10 and suppressed RC (92+/-12%) in contrast to ICOSlow Treg, which mediated low suppression (21+/-15%; p<or=0.0028).

Conclusion: ICOShigh Treg can induce diverse immune responses in RC, depending on activation signals and cytokines present. ICOShigh Treg induce Tr1 or Th2 cells depending on the activation state of RC. In a "Tr1" cytokine milieu, ICOShigh Treg transit to Tr1.

Citing Articles

ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma.

Mallardo D, Fordellone M, Ottaviano M, Marano G, Vitale M, Mallardo M Int J Mol Sci. 2024; 25(22).

PMID: 39596506 PMC: 11594639. DOI: 10.3390/ijms252212439.


Osteopontin Regulates Treg Cell Stability and Function with Implications for Anti-Tumor Immunity and Autoimmunity.

Vakrakou A, Kourepini E, Skordos I, Nieto N, Panoutsakopoulou V, Paschalidis N Cancers (Basel). 2024; 16(17).

PMID: 39272810 PMC: 11393878. DOI: 10.3390/cancers16172952.


Distinct Localization, Transcriptional Profiles, and Functionality in Early Life Tonsil Regulatory T Cells.

Verma S, Bradley M, Gray J, Dogra P, Caron D, Maurrasse S J Immunol. 2024; 213(3):306-316.

PMID: 38905110 PMC: 11304551. DOI: 10.4049/jimmunol.2300890.


Prognostic and therapeutic potential of imbalance between PD-1+CD8 and ICOS+Treg cells in advanced HBV-HCC.

Yan F, Zhu B, Shi K, Zhang Y, Zeng X, Zhang Q Cancer Sci. 2024; 115(8):2553-2564.

PMID: 38877825 PMC: 11309941. DOI: 10.1111/cas.16247.


Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules.

Hazrati A, Malekpour K, Khorramdelazad H, Rajaei S, Hashemi S Biomark Res. 2024; 12(1):35.

PMID: 38515166 PMC: 10958918. DOI: 10.1186/s40364-024-00580-2.